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A systematic review and meta-analysis of studies 
evaluating the performance of point-of-care tests for 
human papillomavirus screening
Helen Kelly,1 Philippe Mayaud,1 Michel Segondy,2 Nitika Pant Pai,3 
Rosanna W Peeling1
Summary
Background High-risk human papillomavirus (HPV) is 
a necessary cause of high-grade cervical intraepithelial 
neoplasia (grade 2 or higher, CIN2+). Simplified and 
rapid HPV DNA assays designed for use in resource-
limited settings have recently become available.
methods We performed a systematic review and meta-
analysis by searching Medline, Embase, Global Health 
and CINAHL databases for studies from 1 January 2004 
to 25 February 2017 that reported the performance of 
careHPV or OncoE6 for the detection of histological 
CIN2+ in cervical cancer screening. We used bivariate 
models to estimate pooled sensitivity and specificity for 
CIN2+ and CIN3+.
results A total of 29 657 women were included from 
seven studies evaluating the performance of careHPV 
for the detection of CIN2+ and four studies among 
27 845 women for the detection of CIN3+. The pooled 
prevalence for CIN2+ and CIN3+ was 2.3% and 
1.1%, respectively. careHPV had sensitivity and specificity 
of 88.1% (95% CI 81.4 to 92.7) and 83.7% (95% CI 
74.9 to 89.8), respectively, for CIN2+ and 90.3% (95% 
CI 83.4 to 94.5) and 85.3% (95% CI 73.1 to 92.5), 
respectively, for CIN3+, using clinician-collected cervical 
specimen. The corresponding pooled estimates using 
self-collected vaginal swabs were 73.6% (95% CI 64.9 
to 80.8) and 88.0% (95% CI 79.1 to 93.5) for CIN2+ 
and 75.2% (95% CI 66.8 to 82.0) and 90.6% (95% 
CI 83.4 to 94.9) for CIN3+. Two studies using OncoE6 
reported sensitivity and specificity ranging from 31.3% 
to 42.4% and 99.1%–99.4% for CIN2+, and 53.5% and 
98.9% for CIN3+ for one study.
Conclusion CareHPV has good sensitivity and 
specificity for the detection of CIN2+ and CIN3+, 
but sensitivity was lower using self-collected vaginal 
samples. The specificity is lower in high HPV prevalence 
populations such as women living with HIV. OncoE6 
assay warrants further evaluation.
IntroduCtIon
Human papillomavirus (HPV) is a necessary cause 
of invasive cervical cancer (ICC),1 2 which affects 
nearly 500 000 women around the world every 
year with a mortality of more than 270 000, 
80% of whom live in low and middle income 
(LMIC) countries.3 Cytology-based programmes 
have been the main approach for screening, but 
these are not often available in most of the low/
middle-income countries.4
The WHO 2014 cervical cancer screening 
guidelines recommend that screening should 
be performed at least once between the ages of 
39 and 49 years, and this may be extended to 
women younger than 30 years if there is evidence 
of high risk for high-grade cervical intraepithelial 
neoplasia (grade 2 and above, CIN2+).5 6 However, 
cervical cancer screening coverage, and linkage to 
care, is low in LMIC countries where infrastructure 
and personnel requirements put high demands on 
the health systems.4 Cytology-based programmes 
have improved cervical cancer control in developed 
countries, but implementation in LMIC countries 
is constrained by cost, lack of infrastructure and 
trained staff, and lag time between sample collec-
tion and availability of test result, leading to delays 
or losses in management.7 Visual inspection of the 
cervix using acetic acid (VIA) or Lugol’s iodine 
(VILI) is frequently practised in low-resource 
settings as it can be performed by trained midwives 
and nurses, and requires simple tools to perform 
(speculum, acetic acid, Lugol’s iodine, lamp). 
However, frequent training and supervision is 
required, and the wide variation in its performance 
is attributed to the subjective nature of test interpre-
tation.7–9 An important advantage of visual inspec-
tion is the possibility to link screening to immediate 
management.
Randomised controlled trials have shown that 
HPV-DNA-based screening allows for earlier diag-
nosis of high-grade CIN and can be more effec-
tive in prevention of ICC.10 A single round of the 
Digene Hybrid Capture 2 (HC2) test that detects 13 
high-risk (HR) HPV types (a qualitative assay that 
does not distinguish the individual genotypes) has 
shown to halve the rate of ICC (HR=0.47, 95% CI 
0.32 to 0.69) and ICC-related mortality (HR=0.52, 
95% CI 0.33 to 0.83) compared with standard-
of-care among 131 746 women aged 30–59 years 
in India.10 However, the assay is expensive and 
requires good logistical platforms. The addition 
of good-performance, rapid and affordable point-
of-care (POC) tests would considerably enhance 
access to HPV testing in LMIC. The careHPV test 
(Qiagen) is based on a simplification of the HC2 
test platform. It detects 14 HR-HPV types (16, 18, 
31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68) 
and is optimised for low/middle-income countries: 
the assay needs only a small bench-top work space 
(about 25×50 cm), no mains electricity (battery 
operated) or running water, and can be done by 
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trained staff in roughly 2.5 hours and has a longer shelf-life 
compared with the HC2 assay. New molecular tests with similar 
characteristics, although with different targets, are becoming 
also available on the market. The OncoE6 test (Arbor Vita) is a 
lateral flow immunoassay that detects the E6 oncoprotein from 
HPV16, HPV18 and HPV45, which cause approximately 75% 
of ICC.11
The purpose of this review was to identify tests for the detec-
tion of HR-HPV that met the ASSURED criteria,12 conduct a 
systematic review of the literature and summarise their perfor-
mance characteristics for the detection of CIN2+.
methodS
Index tests
Only rapid/POC tests for the detection of HR HPV that met the 
ASSURED criteria were included (Affordable, Sensitive, Specific, 
User-friendly, Rapid and robust, Equipment-free and Deliverable 
to end-users).12 HR-HPV types were defined using the current 
International Agency for Research on Cancer classification13: 
‘carcinogenic to humans’ (HPV16, 18, 31, 33, 35, 39, 45, 51, 
52, 56, 58, 59) and ‘probable carcinogenic’ (HPV68).
reference or gold standard test
Studies were included if HPV-DNA tests were assessed against 
a histological endpoint of CIN grade 2 or higher (CIN2+). 
Studies with cytological endpoint assessment only were excluded 
because of the lower sensitivity for cytology measures in detec-
tion of high-grade disease.8
Search
We searched Medline, Embase, Global Health and CINAHL 
databases for publications in the English language from 1 
January 2004 to 31 December 2013 using search terms for 
human papillomavirus (HPV), cervical intraepithelial lesions 
(CIN), squamous intraepithelial lesions (SIL), HPV screening; 
Diagnostics; Point of Care; Rapid; Near patient; method; 
test; evaluation; performance and comparison. Reference lists 
of review articles and all articles identified in the systematic 
search were checked. An updated search was performed on 
25 February 2017. All abstracts were screened by one author 
(HK).
Inclusion and exclusion criteria
Eligibility criteria were defined using the PICOS (Population, 
Interventions, Comparisons, Outcomes, Study Design) criteria 
as shown in box 1. Studies evaluating the accuracy of any 
HPV-POC tests commercially available at the time of the review 
were considered for inclusion.
Studies were excluded if the index test was not a rapid test 
for HPV (ie, did not meet the ASSURED criteria), if diagnostic 
accuracies were not compared with a histological endpoint and 
if the studies did not report data to allow for calculation of diag-
nostic accuracy.
Box 1 Inclusion criteria (PICoS)
Population
Any sexually active populations consistent with the WHO 
screening guidelines in any geographical location, female only, 
include HIV-positive patients.
Interventions (index tests)
Any commercially available technology used for HPV-POC testing 
in the field.
Comparators
Other commercially available technology used for HPV testing.
reference standard
Include studies using an acceptable reference standard 
that satisfy the Quality Assessment of Diagnostic Accuracy 
Studies (QUADAS) checklist (Quality assessment—see 
online supplementary table 1). Acceptable reference standard—
histology.
Sample type
Vaginal or cervical swab.
outcomes
Evaluations of accuracy. Include studies calculating sensitivity, 
specificity, Positive Predictive Value (PPV) and Negative 
Predictive Value (NPV; including 95% CIs).
Study design
Cross-sectional or cohort studies evaluating HPV-POC tests 
against histological endpoint of CIN2+ or CIN3+.
other
English language only, human subjects only, 1 January 2004 to 
25 February 2017.
Figure 1 Flowchart for study selection.
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data extraction
From the consensus list, sensitivity and specificity measures were 
extracted by one author (HK) using a standardised form. For 
all studies, the following variables were recorded: year of study, 
study location, study population, outcomes of interest (histo-
logical confirmed lesion CIN2+/CIN3+), HR-HPV prevalence 
and sensitivity and specificity for the detection of CIN2+ and 
CIN3+, where given.
methodological assessment
Included studies were assessed according to the QUADAS-2 
checklist for reporting diagnostic accuracy14 (online supplemen-
tary table 1).
Statistical analysis
The numbers of true positives, false positives, true negatives and 
false negatives were extracted where available. Where sensitivity 
and specificity measures only were given, data were extracted 
to calculate the numbers of true positives, false negatives, true 
negatives and false positives. Forest plots were generated to 
display sensitivity and specificity estimates.
meta-analysis
The bivariate model15 was used to estimate pooled sensitivity 
and specificity estimates using metandi and midas in STATA, 
whereby pairs of sensitivity and specificity are jointly analysed, 
incorporating any correlation that might exist between these two 
measures using a random-effects approach. Heterogeneity across 
studies was assessed using the I2 statistic.16
Separate meta-analyses were performed for the detection of 
CIN2+ and CIN3+ outcomes, and were also performed sepa-
rately for studies that used different specimen types (cervical vs 
vaginal swabs).
To account for correlation between sensitivity and specificity, 
we used the hierarchical summary receiver operating char-
acteristic (HSROC),17 which allows for threshold effects and 
between-study and within-study variability, by allowing both test 
accuracy to vary across studies. The heterogeneity in the forest 
plots were assessed by visually examining the confidence inter-
vals (CIs) of individual studies, and in summary HSROC plots 
by examining the width of the prediction region, with a wider 
prediction region suggesting more heterogeneity.
Sensitivity analysis
Sensitivity analyses could not be performed due to lack of addi-
tional covariate data. Formal assessment of publication bias was 
not performed due to low number of studies.
Data were analysed using Stata V.14 (Stata Statistical Software).
This review was reported according to the Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses (PRISMA)18 
and the Meta-analysis of Observational Studies in Epidemiology 
(MOOSE) guidelines.19
reSultS
Search result
The first review up to 31 December 2013 identified 1364 publi-
cations through Medline, Embase, Global Health and CINAHL 
library searches, which reported performance measures for 
HPV DNA point-of-care tests for the detection of CIN2+ 
(figure 1), of which 1359 were excluded after abstract review 
because the assays did not meet the ASSURED criteria, leaving 
five publications for full-text review. Finally, two publications20 21 
satisfied the inclusion criteria. An updated search performed until 
25 February 2017 identified an additional four publications22–25 
that satisfied the inclusion criteria. Two further publications26 27 
were subsequently identified in June 2017. The reviews identi-
fied only two tests that appeared to satisfy the ASSURED criteria 
(careHPV (Qiagen) targeting the HR-HPV types HPV16/18/31
/33/35/39/45/51/52/56/58/59/66/68 and OncoE6 (Arbor Vita) 
targeting the HR-HPV types HPV16/18/45), which had publi-
cation material that could be assessed. The characteristics of the 
included publications are summarised in Table 1. One publica-
tion24 provided performance estimates for two countries and 
was considered as two separate populations in the analysis; one 
publication23 provided performance estimates for four countries 
and was considered as four separate populations in the analysis, 
and one publication27 provided performance estimates sepa-
rately for women living with HIV (WLHIV) and HIV-negative 
women and was considered as two populations. This resulted 
in 12 separate populations included in the final analysis, among 
29 657 women. Two studies measured the performance of 
careHPV for CIN2+ detection among 1215 WLHIV in Burkina 
Faso and South Africa,24 and Uganda.27
Among seven studies (twelve populations) evaluating the 
careHPV test (table 1), all evaluated the performance of 
careHPV test for the detection of CIN2+ and four studies 
(eight populations) evaluated its performance for the detec-
tion of CIN3+20 22–24 using clinician-collected cervical swabs. 
Four studies (eight populations) evaluated the performance of 
careHPV for the detection of CIN2+20 22 23 27 and three studies 
(six populations) for CIN3+20 22 23 using self-sampled vaginal 
swabs. All studies evaluating the performance of careHPV used a 
cut-off of 1 pg/mL for defining test positivity.
Two studies evaluated the performance of OncoE6 test for the 
detection of CIN2+22 25 and one study for CIN3+22 using clini-
cian-collected cervical swabs.
The CarehPV test for the detection of CIn2+ and CIn3+
The sensitivity and specificity estimates for CIN2+ for indi-
vidual populations are summarised in figure 2 (clinician-col-
lected cervical swabs) and figure 3 (self-collected vaginal swabs). 
Sensitivity and specificity for CIN3+ for individual populations 
are summarised in figure 4 (clinician-collected cervical swab) 
and figure 5 (self-collected vaginal swab). The pooled summary 
estimates are summarised in table 2.
The careHPV test had a sensitivity of 88.1% (95% CI 81.4 to 
92.7) and specificity of 83.7% (95% CI 74.9 to 89.8) for CIN2+ 
detection using clinician-collected cervical swabs (table 2), and 
a sensitivity of 73.6% (95% CI 64.9 to 80.8) and specificity of 
88.0% (95% CI 79.1 to 93.5) using self-collected vaginal swabs.
The corresponding pooled estimates for sensitivity and speci-
ficity for CIN3+ were 90.3% (95% CI 83.4 to 94.5) and 85.3% 
(95% CI 73.1 to 92.5), respectively, using cervical swabs and 
75.2% (95% CI 66.8 to 82.0) and 90.6% (95% CI 83.4 to 94.9) 
using vaginal swabs. Heterogeneity across studies was high for 
both CIN2+ and CIN3+ outcomes (table 2).
When restricting the analysis to six studies (nine populations) 
among the general population of women using clinician-col-
lected cervical swabs, the sensitivity for CIN2+ was similar to 
the overall pooled result (84.9%, 95% CI 76.8 to 90.5; table 2), 
but specificity was higher (88.6%, 95% CI 76.8 to 90.5). The 
pooled estimates for the 1215 WLHIV in Burkina Faso, South 
Africa and Uganda were 93.7% (95% CI 86.8 to 97.7) and 
58.8% (95% CI 55.9 to 61.7) for sensitivity and specificity, 
respectively (data not shown).24 27
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OncoE6 for the detection of CIN2+ and CIN3+
There were two studies that evaluated the performance of 
OncoE6 for the detection of CIN2+22 25 among 7621 women 
and CIN3+ among 7421 women,22 and among 200 WLHIV.25 
Zhao et al22 reported a sensitivity and specificity of 42.4% and 
99.1%, respectively, for the detection of CIN2+, and 53.5% 
and 98.9%, respectively, for the detection of CIN3+ among 
HIV-negative women in China. In Zambia, Chibwesha et al25 
reported a sensitivity and specificity of 31.3% (95% CI 16 to 
50) and 99.4% (95% CI 97 to 100), respectively, for CIN2+ 
detection among WLHIV.
methodological assessment
According to the QUADAS criteria (online supplementary table 
1), the quality of the papers included was acceptable, but with 
some omissions in reporting on the training of test operators, 
mechanism for blinding of index and reference test and how 
indeterminate results were handled.
dISCuSSIon
This review found that the careHPV test had good sensitivity 
and specificity for the detection of CIN2+ (88.1% and 83.7%, 
respectively) and CIN3+ (90.3% and 85.3%, respectively) using 
clinician-collected swabs. While specificity remained high when 
using self-collected vaginal swabs, the sensitivity for CIN2+ and 
CIN3+ was lower than when using clinician-collected swabs 
(73.6% and 75.2%, respectively).
The pooled performance estimates in this review suggest that 
while the careHPV test has similar specificity to that reported for 
the Hybrid Capture II (HCII) assay, the sensitivity is lower than 
what has been previously reported in other meta-analyses of 
HCII performance.28 This is consistent with a recent meta-anal-
ysis29 that directly compared the performance of the two assays 
and reported a relative sensitivity for the careHPV test compared 
with the HCII assay of 0.86 (95% CI 0.79 to 0.94) and relative 
specificity of 1.01 (95% CI 0.99 to 1.03) for CIN2+.
Compared with the other screening modalities, visual inspec-
tion and cervical cytology, the careHPV test had higher sensi-
tivity but similar specificity for the detection of CIN2+. In a 
meta-analysis of 21 studies from sub-Saharan Africa and India 
among over 58 000 women,7 8 VIA showed moderate sensitivity 
for the detection of CIN2+ (pooled estimate: 79.2%–82.4%) 
and specificity (84.7%–87.4%). VILI performed even better 
with higher sensitivity (CIN2+: 91.2%–95.1%; CIN3+: 
93.8%) and similar specificity (CIN2+: 84.5%–87.2%; CIN3+: 
83.8%). However, sensitivity has been reported to be as low as 
50% in other studies.9 The wide variation in its performance is 
attributed to the subjective nature of test interpretation. High 
Figure 2 Meta-analysis of the careHPV test performance (sensitivity and specificity) for CIN2+ detection using clinician-collected cervical swabs 
among 12 populations. *studies among women living with hIV
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rates of positivity have resulted in over-referral to colposcopy 
services and overtreatment.30 Despite this, a single round of 
VIA screening has been associated with a 25%–35% reduction 
in cervical cancer incidence, cervical cancer mortality and the 
frequency of CIN2+ lesions, in studies in Thailand, Ghana and 
Zambia.31–33
The careHPV test also performed better than cervical 
cytology. In a meta-analysis of studies evaluating performance 
of screening in Africa and India,8 cytology, whether using 
positive test result cut-offs of atypical squamous cells of unde-
termined significance and greater (≥ASCUS), low-grade squa-
mous intraepithelial lesions (≥LSIL) or high-grade squamous 
intraepithelial lesions (≥HSIL), had poor sensitivity for the 
detection of CIN2+ (range: 42.6 for ≥HSIL to 57.0% for 
≥ASCUS) and CIN3+ (range: 51.6%–63.0%) but high spec-
ificity (range: 92.8%–99.3% and 92.3%–99.0% for CIN2+ 
and CIN3+, respectively).
hPV-dna testing among women living with hIV
The careHPV test was shown to have good sensitivity but 
lower specificity for the detection of CIN2+ among WLHIV in 
Burkina Faso, South Africa and Uganda in this review compared 
with the general population,24 27 similar to what was reported 
for HCII among WLHIV in South Africa.34 HPV testing may 
detect many transient infections, which do not progress to 
CIN2+, meaning that its specificity for high-grade CIN can be 
low. A recent review of HPV-DNA-based tests for the detection 
of cervical lesions reported that for a 10% increase in HR-HPV 
prevalence, HR-HPV-DNA-based test specificity for CIN2+ 
detection decreased by 8.4% (95% CI 8.0% to 8.8%),35 which 
has important implications for HIV-positive populations who 
have a high prevalence of HR HPV. Segondy et al also reported 
an increase in specificity with increasing CD4+ cell count and 
among women on antiretroviral therapy (ART), corresponding 
with a decrease in HR-HPV prevalence with increasing CD4+ 
cell count and prolonged duration of ART use. Studies have 
shown that women are at decreased risk of CIN2+ if ART is initi-
ated at higher CD4+ counts (>500 cells/mm3),36 and prolonged 
ART duration and high CD4+ cell count are associated with a 
reduction in HR-HPV prevalence and persistence.37 38
The biggest contribution of POC-HPV testing is the possi-
bility of decentralising screening, increasing the number of 
women who enter the screening and management process 
more promptly and therefore may ultimately contribute to 
the decrease of incidence of high-grade cervical lesions. The 
slightly lower sensitivity and specificity for vaginal self-sam-
pling compared with clinician-collected cervical samples in 
this review were similar to that in a large meta-analysis that 
Figure 3 Meta-analysis of the careHPV test performance (sensitivity and specificity) for CIN2+ detection using self-collected vaginal swabs among 
eight populations. *studies among women living with hIV
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reported a relative sensitivity of 0.88 (95% CI 0.85 to 0.91) 
and specificity of 0.96 (95% CI 0.95 to 0.97) for CIN2+ 
using vaginal self-sampling compared with clinician-collected 
cervical samples.39 However, the possibility of self-sampling 
may allow for an increase in uptake of testing especially in 
settings where self-sampling might be preferred for cultural 
or logistical reasons. A number of studies have evaluated the 
acceptability and feasibility of the self-sampling using the 
careHPV test, and for some the concordance of results. A study 
of 431 women in rural Roi-et Province in Thailand40 reported 
that 91% found the self-swabbing acceptable, 71% preferred 
the self-swab to a clinician swab and 95% returned for same-day 
follow-up. In a study among 518 women in El Salvador,41 
38.8% preferred self-collection and 31.9% preferred provider 
collection. In a study among 194 women in Ghana (50% of 
whom are WLHIV), 76.3% women found self-collection very 
easy/easy to obtain, 57.7% preferred self-collection to clini-
cian collection and 61.9% felt self-collection would increase 
their likelihood to access cervical cancer screening; in that 
study, the concordance of the careHPV test results between 
self-collected and clinician-collected samples was 94.2%.42 
Hence, despite the lower sensitivity of the careHPV test using 
vaginal self-swabs in this review, self-collection coupled with 
POC testing has the potential to increase coverage of screening 
and impact on disease rates. Prospective studies are warranted 
to compare the effectiveness of vaginal self-sampling over clin-
ic-based cervical sampling in terms of numbers of CIN identi-
fied and managed.
The low sensitivity but high specificity of the OncoE6 test, 
which targets HPV16, HPV18 and HPV45, for CIN2+ detec-
tion suggests it may be useful as a ‘screen-and-treat’ or triage 
test; however, further studies are warranted, especially in settings 
where HPV vaccination has been introduced.
limitations
A major drawback of the evaluation of HPV POC tests against 
a relatively rare disease outcome such as CIN2+ is that it is not 
a direct comparison of the detection of the infection that may 
cause disease several years later. Most HR-HPV infections are 
transient and will not all cause severe histological changes. There-
fore, a measure of persistent infection at two time points, or a 
marker of transformative or integrative infection, might increase 
specificity. Furthermore, it is believed that some HR-HPV types, 
such as HPV16, HPV18 and HPV45, might have greater onco-
genic potential.
There was significant heterogeneity across studies (I2, 
table 2), which may be attributed to the variation in HR-HPV 
Figure 4 Meta-analysis of the careHPV test performance (sensitivity and specificity) for CIN3+ detection using clinician-collected cervical swabs 
among eight populations. *studies among women living with hIV
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prevalence across studies. WLHIV in Burkina Faso, South 
Africa and Uganda had the highest prevalence (46.5%, 43.8% 
and 44.9%, respectively), but excluding these studies did not 
lead to a reduction in heterogeneity. HR HPV was also high 
among HIV-negative women in Uganda (20.2%), Nigeria 
(25.1%) and China (18.0%). Another study in Rwanda43 
reported that the careHPV test positivity was higher among 
1289 WLHIV compared with 1675 HIV-negative women 
(31.8% vs 8.2%, respectively), but the study did not measure 
its performance for CIN2+ detection.
There was potential bias attributed to biopsy indication in 
the included studies. Most studies maximised the chances of 
obtaining histological results by basing biopsy decision on 
positivity of any of the screening tests, which included visual 
inspection, cervical cytology and HPV-DNA tests. Women 
negative by all tests were considered to be at extremely low 
risk of CIN2 since in particular HPV DNA and cytology have 
very high negative predictive values for CIN2 diagnosis.44 
There is potentially greater risk of ascertainment bias in 
studies with lower prevalence of HR HPV (table 2), especially 
among the studies that used self-collected vaginal specimens 
which had lower sensitivity for CIN2+. Relative accuracy esti-
mates of the careHPV test compared with other HPV assays 
would allow for a comparability measure of the different HPV 
assays, taking into account the heterogeneity across studies 
and the effects of sampling devices, quality and histological 
endpoint determination. There were too few studies evalu-
ating the performance of the OncoE6 test to conduct a formal 
pooling analysis.
New tests for HPV detection, such as the Xpert HPV, 
look promising in terms of performance for the detection 
of CIN2+ compared with HC2 or HPV genotyping,25 45 46 
but were not considered to satisfy the ASSURED criteria for 
this review. Over time and with lower costs, such tests may 
qualify, especially if investment is made in the platform, as is 
the case for countries like South Africa, which has introduced 
Xpert for Mycobacterium tuberculosis diagnosis nationwide.
ConCluSIon
The careHPV test performs as well as other screening modal-
ities, such as visual inspection and cervical cytology, and has 
the added advantage of allowing for self-sampling that can 
increase coverage and uptake of screening. HPV-DNA testing 
is, however, less specific among WLHIV and could result 
in more false-positive results and over-referral for colpos-
copy in this population. The possibility for future HPV-POC 
tests to distinguish between certain HPV types, to deter-
mine persistence or transformation/integration stages, might 
improve on their performance.
Figure 5 Meta-analysis of the careHPV test performance (sensitivity and specificity) for CIN3+ detection using self-collected vaginal swabs among 
six populations.
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